How Much Is Allopurinol Without Insurance?

The average cost of 30 generic (allopurinol) tablets, each 300mg, is $31.13. By using the WebMDRx coupon, you can get allopurinol for $4.99, which is an 84 percent discount.

How much is allopurinol for gout?

Allopurinol is a medication that is used to treat gouty arthritis, also known as gout, and kidney stones. Gout is caused by crystals of a chemical called uric acid in the joints, most commonly in the big toe, but it can affect any joint. The enzyme xanthine oxidase is inhibited by allopurinol. The body is prevented from creating too much uric acid by this inhibition.

Tablets of allopurinol are available. The typical daily dose is 100 to 300 mg, divided into one or two doses.

Allopurinol costs $7 to $45 for a bottle of 90 tablets with a 300 mg dosage and a coupon.

Allopurinol is a prescription medicine that must be prescribed by a physician or qualified prescriber. What if I told you that QuickMD can treat gout via telemedicine and prescribe allopurinol over the internet. There is no need for insurance.

Is there a generic for allopurinol?

Allopurinol is a kind of allopurinol that is used to It comes in both generic and brand names. Most Medicare and insurance plans cover generic allopurinol, however some drugstore coupons or cash pricing may be lower.

How expensive is gout medicine?

Gout is a rheumatic illness that affects roughly 3.9 percent of individuals in the United States (8.3 million), with males nearly 40 percent more likely than women to be affected. Hyperuricemia, or high uric acid levels more than 6.8 mg/dL, is the major cause of gout, which results in the production of monosodium urate crystals in joint tissues. 3,4 Gout begins as an acute bout of arthritis in the metatarsalphalangeal joint near the base of the big toe, which is the most prevalent location. 5 Lifestyle-related behaviors such as alcohol drinking and purine-rich meals, particularly organ meats and fatty fishes, are risk factors for gout. 6 Obesity, diabetes, and renal insufficiency, as well as drugs such as diuretics and chemotherapeutic agents, all increase the risk of gout. 6 Acute and chronic gout have different therapeutic aims, as do the drugs employed in each case (

).7,8 The purpose of treatment for an acute gout attack is to relieve discomfort by reducing inflammation. 7 Over-the-counter nonsteroidal anti-inflammatory medications (NSAIDs), prescription corticosteroids, and colchicine are commonly used to do this. The goal of treatment for people with chronic gout is to reduce the frequency of painful episodes by lowering and maintaining uric acid concentrations below 6 mg/dL using a mix of nonpharmacological (dietary and lifestyle changes) and pharmacological treatments. 7

In the treatment of chronic gout, the American College of Rheumatology (ACR) recommends first-line pharmacologic prevention with a xanthine oxidase inhibitor (XOI), such as allopurinol or febuxostat, as well as low-dose colchicine or an NSAID.

8 When allopurinol or febuxostat are contraindicated or a patient has exhibited intolerance to at least one of the first-line medicines, probenecid, a uricosuric, is recommended as an alternative first-line agent. 7 In refractory illness, the ACR also classified a combination of an XOI and a uricosuric as a second-line treatment. Pegloticase, a recombinant uricase, is a newer therapeutic option reserved as a third-line medication in cases of refractory disease in which a patient has failed or was unable to tolerate a suitably dosed oral urate-lowering therapy. Pegloticase is a biweekly infusion that is given in a healthcare environment. 9

Until recently, the cost of medication for the treatment of persistent gout was quite modest, with a single medication costing anywhere from $18 to $100 each month, depending on the severity and length of the disease.

10 However, prolonged gout treatment may necessitate many drugs, with some researchers estimating a combined monthly cost of more than $200.

11 Because of federal policy decisions and pipeline advancements, the cost of gout medicines is expected to skyrocket. The US Food and Drug Administration (FDA) announced a new drug safety proposal in June 2006, with the goal of removing drugs like colchicine from the market that had not previously been needed to demonstrate safety or efficacy. 12 The FDA awarded commercial exclusivity to firms that undertook the appropriate safety and efficacy studies in order to encourage review of pharmaceuticals affected by this initiative. 12,13 URL Pharma, a generic drugmaker that has subsequently been bought by Takeda Pharmaceutical Company Limited, undertook clinical trials in 2007 to assess the efficacy of colchicine and determine the least effective dose for the treatment of gout. 13 In 2009, the firm was given three years of market exclusivity for its colchicine formulation, Colcrys, after identifying a lower-dose regimen with an incidence of side events comparable to placebo. 13,14 Following this approval, the FDA ordered that all unapproved single-ingredient oral colchicine treatments be removed from the market, resulting in an unanticipated increase in treatment costs from pennies to roughly $5 per day. 12,13

The prevalence of prescription drugs used in the treatment of gout will be investigated in this paper. In addition, the impact of Colcrys on gout treatment usage and cost will be investigated. Finally, the present status and economic implications of recently launched and in-development gout treatments will be examined.

De-identified CVS Caremark pharmacy claims data were used in this descriptive analysis. Adult members who had a pharmacy claim for at least one of the drugs primarily used to treat gout between 2009 and 2012 were chosen for analysis. Colchicine, febuxostat, pegloticase, colchicine plus probenecid, and allopurinol were among the drugs investigated. Each member’s age and gender were calculated using information from their most recent claim. The cost per utilizer per day and the generic dispensing rate (GDR) were also computed. The term “cost” is defined in this study as the entire amount spent for the drug (the payer and member portions combined). SAS 9.1 was used to conduct the descriptive analysis (SAS Institute, Cary, North Carolina).

Which is better allopurinol or febuxostat?

Conclusions. Febuxostat was more efficacious than allopurinol at the regularly used fixed daily dose of 300 mg in decreasing serum urate at a daily dose of 80 mg or 120 mg. All therapy groups saw similar reductions in gout flares and tophus area.

What is the brand name for allopurinol?

Generic and brand-name versions of allopurinol oral tablet are available. Zyloprim and Lopurin are two brand names for the same drug. An injection of allopurinol is also given by a healthcare expert in the hospital. Gout, high serum uric acid levels, and recurring kidney stones are all treated with allopurinol oral tablet.

Is allopurinol hard on kidneys?

WASHINGTON, DC – According to new data presented this week at the 2016 ACR/ARHP Annual Meeting in Washington, allopurinol, a commonly used therapy for decreasing serum urate levels, does not appear to raise the risk of renal deterioration in gout patients with normal or near-normal kidney function.

Chronic kidney disease (CKD) is a progressive loss of kidney function that, in its advanced stages, can result in fluid, electrolyte, and waste build-up. In some patients, gout, a disorder characterized by excessive amounts of uric acid that can crystallize and settle in joints, might contribute to CKD.

Hyperuricemia, or high serum urate levels in the blood, can induce CKD, however doctors have been wary about prescribing allopurinol to these patients due to the risk of side effects. The risk of allopurinol use in gout patients with normal renal function who need to lower their urate levels was investigated in a study.

“The treatment of gout is frequently ineffective. The common practice of lowering or stopping allopurinol when a patient with gout begins to have a decline in kidney function, which inevitably adds to the poor control of their gout, is exacerbating this poor management “Ana Beatriz Vargas-Santos, PhD, who conducted the research while at Boston University School of Medicine’s Clinical Epidemiology Research and Training Unit, said “However, it is unclear if allopurinol is harmful to kidney function; in fact, some modest trials suggest that it may be useful in preventing renal deterioration. As a result, we looked into the likelihood of developing CKD after starting allopurinol in those who had normal or near-normal renal function. If no such elevated risk is detected, doctors should not stop, halt, or reduce allopurinol doses needlessly when a patient’s kidney function drops, and should instead consider other factors that may be contributing to the renal function reduction.”

The Health Improvement Network (THIN), a database of patients served by general practitioners in the United Kingdom, provided electronic health record data for the study. Patients between the ages of 18 and 89 who had incident gout between 2000 and 2014 and had at least one contact with a general practitioner within a year of the study period were included. They looked at the link between allopurinol use and the development of CKD Stage 3 or above in gout patients. They used a sensitivity analysis to censor study subjects whose exposure to the medicine altered at some point, because patients who started allopurinol therapy may have discontinued and non-users may have started over the study period.

The researchers found 13,727 patients who began using allopurinol and matched them to 13,727 patients who did not take the medicine. The subjects were on average 58 years old, with a BMI of 30, and a four-year follow-up period for both groups. Allopurinol use was not linked to an increased risk of acquiring CKD?Stage 3 disease when compared to non-use, with 1,401 allopurinol initiators and 1,319 non-users developing CKD at?Stage 3 disease, yielding a relative risk of 1.05, which was not statistically significant. They determined that allopurinol can help lower serum urate levels and alleviate gout symptoms without putting the kidneys at danger.

“Our findings help to dispel the myth that allopurinol is damaging to the renal function of gout patients,” Dr. Vargas-Santos remarked. “This could motivate doctors to provide allopurinol at the right dose, leading in better outcomes for these patients. More research, including studies with people with established and advanced chronic renal disease, is needed to better understand this issue.”

The National Institute of Arthritis and Musculoskeletal and Skin Diseases provided funding for this study.